# A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

> **NCT05565391** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 508 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05565391
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2022-11-04
- **Final completion:** 2022-11-04
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565391, "A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05565391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*